Latest revenue
$210.0K
as of 2023-07-31
Latest net income
$-2.5M
as of 2023-07-31
Net margin
-1195.7%
as of 2023-07-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think ANIX is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $82.8M
- Enterprise value
- $83.3M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 5.49×
- Dividend yield
- —
- 52-wk high
- —
- 52-wk low
- —
- Beta
- —
- Shares out
- 33.5M
5-year trend
What this company does
Item 1. Business Overview Anixa Biosciences, Inc. is a biotechnology company developing therapies and vaccines that are focused on critical unmet needs in oncology. Our therapeutics program consists of the development of liraltagene autoleucel (“lira-cel”), a chimeric endocrine receptor-T cell therapy, which is a novel form of chimeric antigen receptor-T cell (“CAR-T”) technology, initially focused on treating ovarian cancer, that is being developed at our subsidiary, Certainty Therapeutics, Inc. (“Certainty”). Our vaccine programs include (i) the development of a vaccine against breast cancer, (ii) the development of a vaccine against ovarian cancer, and (iii) a vaccine discovery program…
AI summary unavailable — showing raw filing excerpt
Generated from ANIX's filing dated 2026-01-12
Key risks
Item 1A. Risk Factors Our business involves a high degree of risk and uncertainty, including the following risks and uncertainties: Risks Related to Our Financial Condition and Operations We have a history of losses and may incur additional losses in the future. On a cumulative basis, we have sustained substantial losses and negative cash flows from operations since our inception. As of October 31, 2025, our accumulated deficit was approximately $251,677,000, and we had approximately $15,174,000 in cash, cash equivalents and short-term investments, and working capital of approximately $13,920,000. In fiscal year 2025, we incurred losses of approximately $11,028,000 and we experienced…
AI summary unavailable — showing raw filing excerpt
Generated from ANIX's filing dated 2026-01-12
Profitability
Operating margin
-5243.3%
104.6%Net margin
-4671.9%
84.8%Return on equity
-72.1%
14.8%Return on assets
-68.0%
16.9%Leverage
Debt / equity
0.06×
23.9%Debt / assets
5.7%
22.5%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-01-31 | — | — | $-2.6M | +19.4% | — |
Q4 2025 2025-10-31 | — | — | $-2.7M | +6.5% | — |
Q3 2025 2025-07-31 | — | — | $-2.3M | +31.1% | — |
Q2 2025 2025-04-30 | — | — | $-2.8M | +11.1% | — |
Q1 2025 2025-01-31 | — | — | $-3.2M | +2.2% | — |
Q4 2024 2024-10-31 | — | — | $-2.9M | — | — |
Q3 2024 2024-07-31 | — | — | $-3.3M | -30.5% | — |
Q2 2024 2024-04-30 | — | — | $-3.1M | — | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ANIX — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$141.1K
Insider selling
$0
Net activity
+$141.1K
Distinct insiders
3
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ANIX
Institutional value
$8.7M
Total shares held
3.5M
Distinct holders
38
-32 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 1.3M | $3.4M | — | New |
| 2 | UBS Group AG | 551.6K | $1.4M | +92.6K (+20.2%) | Added |
| 3 | D.A. DAVIDSON & CO. | 539.3K | $1.4M | +0 (+0.0%) | No change |
| 4 | VANGUARD FIDUCIARY TRUST CO | 191.1K | $493.0K | — | New |
| 5 | BlackRock, Inc. | 170.1K | $438.9K | +6.1K (+3.7%) | Added |
| 6 | LPL Financial LLC | 81.0K | $208.9K | -8.6K (-9.6%) | Trimmed |
| 7 | CoreCap Advisors, LLC | 52.0K | $134.2K | +4.0K (+8.3%) | Added |
| 8 | Kestra Advisory Services, LLC | 51.0K | $131.6K | +25.0K (+96.2%) | Added |
| 9 | Bank of New York Mellon Corp | 47.4K | $122.4K | -10.8K (-18.6%) | Trimmed |
| 10 | Westside Investment Management, Inc. | 47.0K | $121.3K | +3.0K (+6.8%) | Added |
| 11 | HighTower Advisors, LLC | 41.5K | $107.2K | +400 (+1.0%) | Added |
| 12 | Gemmer Asset Management LLC | 35.0K | $90.3K | +0 (+0.0%) | No change |
| 13 | Vontobel Holding Ltd. | 30.0K | $77.4K | — | New |
| 14 | CIBC Bancorp USA Inc. | 26.6K | $68.6K | — | New |
| 15 | NATIONS FINANCIAL GROUP INC, /IA/ /ADV | 22.5K | $58.0K | +0 (+0.0%) | No change |
| 16 | KEYBANK NATIONAL ASSOCIATION/OH | 15.8K | $40.8K | +0 (+0.0%) | No change |
| 17 | Robertson Stephens Wealth Management, LLC | 15.6K | $40.4K | +0 (+0.0%) | No change |
| 18 | Dakota Wealth Management | 15.0K | $38.7K | +0 (+0.0%) | No change |
| 19 | World Investment Advisors | 14.6K | $37.7K | -14.6K (-50.0%) | Trimmed |
| 20 | NewEdge Wealth, LLC | 12.5K | $32.3K | +0 (+0.0%) | No change |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ANIX's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.